Assessment of rheumatoid arthritis
Sir: Dr Larsen,' referring to a recent viewpoint article,2 says that some workers have apparently changed their minds about the assessment of rheumatoid arthritis (RA). I think the comment is directed at me and am glad of an opportunity to reply. Table 2 of the viewpoint article shows the consensus view was that for assessing RA over one to two year periods 'clinical and laboratory indices of disease activity' were appropriate. This is not in conflict with views expressed by us,3 and to which Dr Larsen refers. There are small differences in matters of detail. Dr Larsen specifically mentions 'clinical score'. We proposed this years ago3 and later showed that there was a high degree of similarity between it and some other clinical measures.4 Which method to use is therefore a matter of personal choice; I still prefer 'clinical score', but a consensus meeting is not the place to promote individual preferences. Which laboratory tests to use is, similarly, best decided by personal preference.
Two more difficult problems are how to assess RA over periods exceeding two years and also the place of x rays. With regard to the first, I still believe that the clinical/laboratory approach is an essential background. It must be said, however, that as time goes by some extra guides become increasingly necessary; I was in agreement with the views about this expressed at the meeting and set out in the viewpoint. In particular, the morbidity assessment suggested seems likely to be useful.
On the question of x rays, Dr Larsen must surely concede that there are at least two difficulties; firstly, the correlation between x ray change and change in overall function is not very high; secondly, x ray changes in, for example, the hands, do not reflect the impact of changes in a big joint. Hence the comment that less value is now placed on x rays. Nevertheless, I suspect that most people, uncertain about the progression of RA or the effects of a drug in a particular patient, will still be influenced by x ray findings; and I do not think x rays will be abandoned as part of the methodology of trials.
The viewpoint did not, it seems to me, point to changes of mind; the meeting did provide a useful forum where ideas, shaped by experience, could be re-examined and perhaps refined-then submitted for wider appraisal. What should we hope to achieve when treating rheumatoid arthritis? Ann Rheum Dis 1989; 48:
